菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Accelerator, incubator, innovation, and
early-stage investor partnership program

Enable the Molecule Program Program Presentation

 

We would like to introduce to you “Enable the Molecule”, WuXi Biologics’ program to support startups focused on biologics and vaccines

 

Date: Tuesday, May 14th, 2024

Time: 9:00am

Location: Bio-Innovation Institute (Ole Maaløes Vej 3, Copenhagen, Denmark)

Room: M0.8 Oxygen

 

Presentation by:

Louk Pechtold, Snr Director Corporate Development & Investments

Richart Hart, Snr Director Business Development Europe

Yucai Li, Executive Director CMC – Europe

Michelle Wang, Director Business Development Research Services – Europe

 

Enable the Molecule Program provides startups with the necessary tools and resources to expedite biologics and vaccine development. It provides free development advice and even (non-equity diluting) financial grants to startups, which are associated with incubators, accelerators, VCs/investors, WuXi Biologics is collaborating with. The program already collaborates with 26 leading partners in USA, EU and Asia.

 

 

Key Program Partner Details:

• Enable The Molecule is non-exclusive

• Startups are free to be also associated with other CDMOs

• No fees, no equity, no payback

• Current and former BII Startups developing biologicals or vaccines are eligible to apply

 

We will present to you WuXi Biologics and the Enable The Molecule program. WuXi Biologics experts will be available to answer any questions you might have.

 

Register now for the complimentary breakfast presentation on Monday, November 27th to learn more about the Enable the Molecule Program

 

To learn more, download our flyer


About WuXi Biologics

WuXi Biologics is a leading contract research, development and manufacturing organization (CRDMO) that provides end-to-end capabilities to healthcare organizations worldwide. With operations in Germany, Ireland, the United States, Singapore and China, we enable our partners to effectively and efficiently bring biologics and vaccines to patients worldwide through our comprehensive and high-quality drug development model.